Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill is filed in its originating chamber and assigned a number.
Filed in the House.
Next: In Committee
Members of the committee(s) the bill was referred to
Modernizes how clinical trials are run to make medical research faster and more efficient.
The problem
Clinical trial processes are outdated and slow, making it difficult to test new medicines quickly and limiting patient access to experimental treatments.
The proposal
Updates federal rules for conducting clinical trials to streamline approval processes, reduce paperwork, and allow more flexible trial designs.
The impact
Patients, drug companies, researchers, and the FDA are affected through faster access to new treatments, reduced research costs, and changing regulatory oversight.
Modernizing trial processes could help patients get promising new treatments sooner. This is especially important for people with serious diseases who have limited options.
Streamlined procedures reduce expenses for companies running clinical trials. Lower costs may make it easier for smaller companies to develop new drugs.
Updated rules allow researchers to design trials that work better for different patient populations. This can make trials easier for patients to join.
Faster and cheaper trials encourage more drug development and medical research. This can lead to more treatment options for patients.
Moving trials faster might reduce the time to check for side effects or problems. Less rigorous oversight could put patients at risk.
Streamlining processes might weaken the FDA's ability to catch dangerous issues. This could allow unsafe drugs to reach patients.
Faster trials might favor wealthy regions and larger medical centers. Patients in rural or poor areas could be left behind.
Reducing requirements and paperwork might lower research quality. Bad data from rushed trials could lead to poor treatment recommendations.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.